China's medical products administrator approved Shanghai Haixin Group (SHA:600851) subsidiary Jiangxi Gannan Haixin Pharmaceutical's drug registration and active pharmaceutical ingredient application for its dexmedetomidine hydrochloride injection.

Dexmedetomidine hydrochloride is indicated for sedation during endotracheal intubation and mechanical ventilation for patients undergoing surgery, according to a Tuesday filing with the Shanghai Stock Exchange.

The drug is also used to sedate patients who have been intubated and inserted with a ventilator during intensive care treatment, the filing said.

Shares in the drug company closed 3% lower during Tuesday's afternoon trading.